GSK hails phase 3 win for RSV vaccine in older adults, sparking race to regulators

GSK’s respiratory syncytial virus (RSV) vaccine has hit the mark in a phase 3 trial in older adults, teeing the company up to file for approval by the end of the year. But the data-devoid statement leaves unanswered the big question of how the vaccine will fare in a competitive, blockbuster market.